D-1496-2020 Class III Terminated

Recalled by Taro Pharmaceuticals U.S.A., Inc. — Hawthorne, NY

FDA drug recall D-1496-2020 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Jul 20, 2020 and is designated Class III. Reason for recall: Failed Content Uniformity: bulk lot used to make these two lots was found to have failed content uniformity. The recall status is terminated (terminated Jun 20, 2023). Affected quantity: 7632 tubes.

Recall details

Product Type
Drugs
Report Date
Aug 19, 2020
Initiation Date
Jul 20, 2020
Termination Date
Jun 20, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
7632 tubes

Product description

Clobetasol Propionate Cream USP, 0.05%, a) 15 g tube, NDC: 60429-902-15; b) 45 g tube, NDC: 60429-902-45, Rx Only, For External Use Only, Not for Ophthalmic Use, Mfd by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Marketed by: Golden State Medical Supply, Inc. Camarillo, CA 93012.

Reason for recall

Failed Content Uniformity: bulk lot used to make these two lots was found to have failed content uniformity.

Distribution pattern

Nationwide in the U.S.

Code information

a) AB28353, Exp 12/31/2021; b) AB40178, Exp 12/31/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1496-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1496-2020. Report a data issue: hello@regdatalab.com.